Avalo Therapeutics Inc

+0.04 (+36.74%)
6:16:50 PM EDT: $0.17 +0.01 (+4.85%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)3.41M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1 Million
Adjusted EPS-$1.10
See more estimates
10-Day MA$0.13
50-Day MA$0.16
200-Day MA$2.39
See more pivots

Avalo Therapeutics Inc Stock, NASDAQ:AVTX

540 Gaither Road, Suite 400, Rockville, Maryland 20850
United States of America
Phone: +1.410.522.8707
Number of Employees: 20


Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.